Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease

Summary

This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome. Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome in patients suffering from these conditions. Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and will then be monitored off study treatment for an additional 4 weeks.

Timeline

Start

2012-01

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “Sponsors decision”

Drugs

Indications